Ed F. Haislmaier, the Preston A. Wells Jr senior research fellow at the Institute for Family Community, and Opportunity at The Heritage Foundation, talks about the impact of new business partnerships on healthcare costs.
Ed F. Haislmaier, the Preston A. Wells Jr senior research fellow at the Institute for Family Community, and Opportunity at The Heritage Foundation, talks about the impact of new business partnerships on healthcare costs.
Transcript
What impact do you see of recent nontraditional mergers and partnerships — CVS-Aetna and Amazon-JP Morgan-Berkshire Hathaway – having on healthcare costs?
I’m keeping an open but skeptical mind about both of those partnerships. I’m not sure about the CVS-Aetna partnership as really creating that much synergy. I’m willing to be persuaded but it just doesn’t seem to be a synergistic approach. The question about Amazon and Berkshire and JP Morgan Chase—that is even less clear. It does seem to have the feel of large employers getting together to finally figure out how to buy smarter, which is something we’ve seen happen before with mixed results.
We’ve had business coalitions on healthcare and things like that. Both of those are very early stages and I’m willing to say that something might happen, but I’m skeptical on both.
The Center for American Progress recently released a framework called Medicare Extra for All, similar to Senator Bernie Sanders’ own proposal — what is your take on these types of proposals?
The basic problem that they’re trying to address is the so-called uninsurance. I’m not sure how many uninsured people we actually have left because functionally most of the people, if people are technically insured, a lot of them are functionally insured. In other words, they have access to care, they’re just not in an insurance program.
This is kind of interesting because we’ve seen this with the Affordable Care Act is we’ve seen people get the Affordable Care Act insurance when they need medical care and then drop it. So, do you count those people as insured or uninsured? Because once they’ve been treated, they drop the insurance.
I think the goal of insurance for everybody, while it sounds nice, is really a secondary. The primary goal I think we need to focus on are people getting access to the medical care that they need. How we do that, how we pay for it, becomes a secondary issue.
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More